Kaleido Biosciences, Inc. (KLDO) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Lexington, MA, United States. The current CEO is Mark A. Wingertzahn.
KLDO has IPO date of 2019-02-28, 76 full-time employees, listed on the Other OTC, a market capitalization of $4.26K.
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
